Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Autolus Therapeutics plc
< Previous
1
2
Next >
Autolus Therapeutics announces participation in upcoming conferences
November 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus
October 17, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
October 11, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
September 05, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
August 03, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
July 19, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
July 18, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
July 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces publication in Cancer Immunology Research
June 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
June 20, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
June 16, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
June 06, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
June 02, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to hold Analyst call to highlight data at ASCO from the Pivotal Phase 2 FELIX study of obe-cel data in adult r/r B-ALL
May 22, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA
May 12, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress
May 04, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at ASCO
April 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
April 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
CAH
Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids
April 26, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia in an Oral Presentation at the EBMT 49th Annual Meeting
April 26, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Host Virtual Capital Markets Day
April 25, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
April 20, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Announces Publication in Molecular Therapy
April 04, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics announces resignation of Chief Financial Officer
March 14, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Has No Business Relationship with Silicon Valley Bank
March 13, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress
March 07, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
February 15, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Tickers
AUTL
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.